SCHEMBL22980478

SCHEMBL22980478

CC(N)=NOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.49
PRSS1 P07477 3/20 0.49
PRSS2 P07478 3/20 0.49
PRSS3 P35030 3/20 0.49
MAPT P10636 6/20 0.45
ALDH1A1 P00352 6/20 0.45
LMNA P02545 2/20 0.45
MAPK1 P28482 2/20 0.45
HSP90AA1 P07900 1/20 0.45
PKM P14618 1/20 0.45
XBP1 P17861 1/20 0.45
MPI P34949 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18501727 1.00 F2 (0.49) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL22980477 1.00 F2 (0.49) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL13673554 0.87 F2 (0.55) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL91998 0.85 ALDH1A1 (0.47) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL11528365 0.85 ALDH1A1 (0.47) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL22980394 0.81 F2 (0.45) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL22980392 0.81 F2 (0.45) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL9290737 0.81 F2 (0.47) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL195188 0.81 ALDH1A1 (0.44) F2PRSS1PRSS2PRSS3MAPT
SCHEMBL195187 0.81 ALDH1A1 (0.44) F2PRSS1PRSS2PRSS3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 EP disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 F2 34/4885PRSS1 18/4885PRSS2 45/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 F2 34/4885PRSS1 18/4885PRSS2 45/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 F2 34/4885PRSS1 18/4885PRSS2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.